Stock To Buy: Akums Drugs and Pharmaceuticals is showing early signs of a turnaround after a tough phase for its CDMO business. ICICI Securities has retained a Buy rating and raised the target price to Rs 600, implying a 35 per cent upside from current levels. Stabilising API prices, new export orders from Zambia and Europe, and improving capacity utilisation are expected to drive growth and margins over the next few years.